Ground-breaking Cancer Vaccine

April 10, 2012

The vaccine is being tested against a type of blood cancer, multiple myeloma [the second most common blood cancer]. If the substance works as hoped, its platform technology, VaxHit, could be applied to 90% of all known cancers, including prostate and breast cancer, solid and non-solid tumors.

“In cancer, the body knows something is not quite right but the immune system doesn’t know how to protect itself against the tumor like it does against an infection or virus. This is because cancer cells are the body’s own cells gone wrong,” says Julian Levy, the company’s CFO. “Coupled with that, a cancer patient has a depressed immune system, caused both by the illness and by the treatment.”

The trick is to activate a compromised immune system to mobilize against the threat. A traditional vaccine helps the body’s immune system fend off foreign invaders such as bacteria or viruses and is administered to people who have not yet had the ailment. Therapeutic vaccines, like the one Vaxil has developed, are given to sick people and work more like a drug.

The new vaccine works by “training” T-cells to search and destroy cells with the MUC1 molecule, typically found only on cancer cells. More than 90% of common solid tumor cancers bear the MUC1 molecule, as well as many non-solid tumors, including lymphoma, leukemia, and multiple myeloma.

Advanced-stage cancer will still require chemotherapy or surgery to remove a large tumor, Levy noted, but if the cancer is brought down to size, the body will then be able to fight it, with ImMucin seen as a long-term approach to prevent recurrence. For more information: +972-8-939-6948; info@vaxilbio.com

Source: By David Shear, Ynetnews

Photo Credit: Israel21c